RT Journal Article SR Electronic T1 A novel missense variant in the ATPase domain of ATP8A2 and review of phenotypic variability of ATP8A2-related disorders caused by missense changes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.05.15.24306843 DO 10.1101/2024.05.15.24306843 A1 Flannery, Kyle P. A1 Safwat, Sylvia A1 Matsell, Eli A1 Battula, Namarata A1 Hamed, Ahlam A. A. A1 Mohamed, Inaam N. A1 Elseed, Maha A. A1 Koko, Mahmoud A1 Abubaker, Rayan A1 Abozar, Fatima A1 Elsayed, Liena E. O. A1 Bhise, Vikram A1 Molday, Robert S. A1 Salih, Mustafa A. A1 Yahia, Ashraf A1 Manzini, M. Chiara YR 2024 UL http://medrxiv.org/content/early/2024/05/15/2024.05.15.24306843.abstract AB ATPase, class 1, type 8A, member 2 (ATP8A2) is a P4-ATPase with a critical role in phospholipid translocation across the plasma membrane. Pathogenic variants in ATP8A2 are known to cause cerebellar ataxia, mental retardation, and disequilibrium syndrome 4 (CAMRQ4) which is often associated with encephalopathy, global developmental delay, and severe motor deficits. Here, we present a family with two siblings presenting with global developmental delay, intellectual disability, spasticity, ataxia, nystagmus, and thin corpus callosum. Whole exome sequencing revealed a homozygous missense variant in the nucleotide binding domain of ATP8A2 (p.Leu538Pro) that results in near complete loss of protein expression. This is in line with other missense variants in the same domain leading to protein misfolding and loss of ATPase function. In addition, by performing diffusion-weighted imaging, we identified bilateral hyperintensities in the posterior limbs of the internal capsule suggesting possible microstructural changes in axon tracts that had not been appreciated before and could contribute to the sensorimotor deficits in these individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by funding from the National Institutes of Health (grant #R01NS109149) and the Robert Wood Johnson Foundation (grant #74260) to M.C.M.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees of the Medical Campus, University of Khartoum, Sudan, of the National University, Sudan, and the Institutional Review Board at Rutgers University, United States gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData reported in this study will be made available upon request from the corresponding author.